Cumberland Pharmaceuticals (Cumberland Pharmaceuticals) Cash-to-Debt

: 0.99 (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Cumberland Pharmaceuticals's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.99.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Cumberland Pharmaceuticals couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Cumberland Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

CPIX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.94 Med: 1.75 Max: No Debt
Current: 0.99

During the past 13 years, Cumberland Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 0.94. And the median was 1.75.

CPIX's Cash-to-Debt is ranked better than
51% of 1047 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs CPIX: 0.99

Cumberland Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Cumberland Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Cumberland Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

1.31

1.29

1.68

0.94

0.99

Cumberland Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt																0.94	0.79	0.96	0.99	0.99

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cumberland Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cumberland Pharmaceuticals Cash-to-Debt Distribution

For the Drug Manufacturers industry and Healthcare sector, Cumberland Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Cumberland Pharmaceuticals's Cash-to-Debt falls into.

Cumberland Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Cumberland Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	18.322	/	(0.348	+	18.08)
	=	0.99

Cumberland Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	18.322	/	(0.348	+	18.08)
	=	0.99

Cumberland Pharmaceuticals (NAS:CPIX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Cumberland Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Cumberland Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Cumberland Pharmaceuticals (Cumberland Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cumberland Pharmaceuticals Inc (NAS:CPIX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

1600 West End Avenue, Suite 1300, Nashville, TN, USA, 37203

Website

https://www.cumberlandpharma.com

Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, RediTrex, Sancuso, Vaprisol and Vibativ.

Executives

Todd M. Anthony	officer: Vice Pres Organizational Dev	1600 WEST END AVENUE, SUITE 1300, NASHVILLE TN 37203
Chris T. Bitterman	officer: Vice Pres Sales & Marketing	1600 WEST END AVENUE, SUITE 1300, NASHVILLE TN 37203
Joseph C Galante	director	111 TENTH AVENUE, SUITE 200, NASHVILLE TN 37203
James Jones	director	2525 WEST END AVE., SUITE 950, NASHVILLE TN 37203
Kenneth Krogulski	director	2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Caroline Young	director	2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Brown Martin S Jr	director	850 DIXIE HIGHWAY, LOUISVILLE KY 40210
A J Kazimi	director, 10 percent owner, officer: Chairman and CEO	1207 17TH AVENUE SUITE 103, NASHVILLE TN 37212
Martin E Cearnal	director	31 UPPER MOUNTAIN AVENUE, APARTMENT 2, MONTCLAIR NJ 07042
John M. Hamm	officer: Chief Financial Officer	2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Gordon R Bernard	officer: Senior Vice President	2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Joey A Jacobs	director	830 CRESCENT CENTER DRIVE, SUITE 610, FRANKLIN TN 37067
Michael Bonner	officer: Chief Financial Officer	2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Jonathan Griggs	director	2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Thomas R Lawrence	director	1880 ELLINGTON WAY, AUBURN AL 36830